Health and Healthcare

Amgen : AMGN

All Amgen Articles

701 Articles

Chris Lange | Jun 27, 2018 at 9:00 AM EDT

Short Sellers Run for Cover From Major Biotechs

The June 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jun 12, 2018 at 10:54 AM EDT

Short Sellers Up the Ante For Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data…

Lee Jackson | Jun 1, 2018 at 10:30 AM EDT

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

It’s no surprise that it was only a matter of time before the usage and storage of big data and…

Chris Lange | May 25, 2018 at 9:40 AM EDT

Short Interest Remains Mixed in Major Biotechs

The May 15 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | May 22, 2018 at 11:40 AM EDT

Amgen Wins Another FDA Approval

Amgen shares made a slight gain on Tuesday after it was announced that the FDA approved its treatment of glucocorticoid-induced…

Trey Thoelcke | May 18, 2018 at 8:00 AM EDT

Amgen’s Novel Migraine Treatment Gets Key Approval

Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.

Chris Lange | May 10, 2018 at 10:40 AM EDT

Big Biotechs Scare Off Short Sellers

The April 30 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | May 5, 2018 at 8:40 AM EDT

The Top Biopharma Catalysts Coming in May

Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

Chris Lange | Apr 25, 2018 at 8:40 AM EDT

Major Biotechs Face Rising Tide of Short Interest

The April 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Apr 22, 2018 at 10:15 AM EDT

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and…

Jon C. Ogg | Apr 17, 2018 at 11:35 AM EDT

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S.…

Chris Lange | Apr 11, 2018 at 9:05 AM EDT

Short Sellers Back Way Off Major Biotechs

The March 29 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 27, 2018 at 9:30 AM EDT

Major Biotechs See Rising Tide in Short Interest

The March 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 17, 2018 at 7:55 AM EDT

Even More Biopharma Catalysts Coming Through the End of March

Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

Chris Lange | Mar 12, 2018 at 9:45 AM EDT

Major Biotechs: Tough Call for Short Sellers

The February 28 short interest data have been compared with the previous report, and short interest moves in the selected…

1 … 15 16 17 18 19 … 47

Amgen : AMGN

All Amgen Articles

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Short Interest Remains Mixed in Major Biotechs

Amgen Wins Another FDA Approval

Amgen’s Novel Migraine Treatment Gets Key Approval

Big Biotechs Scare Off Short Sellers

The Top Biopharma Catalysts Coming in May

Major Biotechs Face Rising Tide of Short Interest

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Short Sellers Back Way Off Major Biotechs

Major Biotechs See Rising Tide in Short Interest

Even More Biopharma Catalysts Coming Through the End of March

Major Biotechs: Tough Call for Short Sellers

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Amgen : AMGN

All Amgen Articles

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Short Interest Remains Mixed in Major Biotechs

Amgen Wins Another FDA Approval

Amgen’s Novel Migraine Treatment Gets Key Approval

Big Biotechs Scare Off Short Sellers

The Top Biopharma Catalysts Coming in May

Major Biotechs Face Rising Tide of Short Interest

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Short Sellers Back Way Off Major Biotechs

Major Biotechs See Rising Tide in Short Interest

Even More Biopharma Catalysts Coming Through the End of March

Major Biotechs: Tough Call for Short Sellers

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

Featured Reads

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase